Gilead Sciences, Inc. $GILD Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,742,656 shares of the biopharmaceutical company’s stock after buying an additional 417,237 shares during the quarter. Gilead Sciences accounts for 0.7% of Robeco Institutional Asset Management B.V.’s holdings, making the stock its 22nd largest holding. Robeco Institutional Asset Management B.V.’s holdings in Gilead Sciences were worth $414,948,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Woodward Diversified Capital LLC acquired a new position in Gilead Sciences during the 2nd quarter worth $317,000. Precision Wealth Strategies LLC acquired a new position in Gilead Sciences during the 2nd quarter worth $1,921,000. USA Financial Formulas grew its stake in Gilead Sciences by 24.1% during the 2nd quarter. USA Financial Formulas now owns 30,176 shares of the biopharmaceutical company’s stock worth $3,346,000 after purchasing an additional 5,858 shares in the last quarter. QTR Family Wealth LLC grew its stake in Gilead Sciences by 5.3% during the 2nd quarter. QTR Family Wealth LLC now owns 2,049 shares of the biopharmaceutical company’s stock worth $227,000 after purchasing an additional 104 shares in the last quarter. Finally, Trust Co. of Vermont grew its stake in Gilead Sciences by 2.7% during the 2nd quarter. Trust Co. of Vermont now owns 11,976 shares of the biopharmaceutical company’s stock worth $1,328,000 after purchasing an additional 320 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.1%

Gilead Sciences stock opened at $111.15 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $83.10 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market capitalization of $137.92 billion, a P/E ratio of 22.14, a PEG ratio of 0.75 and a beta of 0.34. The stock has a 50-day simple moving average of $114.47 and a 200-day simple moving average of $109.92.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the previous year, the business earned $2.01 EPS. The business’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.17.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This represents a 1.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 82,000 shares of company stock valued at $9,402,130. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.